NexMed Receives Commitment for $3 Million Line of Credit
EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the NexACT® drug delivery technology, today announced that it has entered into a binding commitment with one of its largest shareholders for a $3 million line of credit. Additional information is available in NexMed’s 8-K filing for this transaction.